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Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks 
ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth 
factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers, and 
can elicit antibody-dependent cell-mediated cytotoxicity. High tumor-expression of 
neuregulin 1 (NRG1), a ligand to HER3, may enhance sensitivity to duligotuzumab.
Methods: This multicenter, open-label, randomized phase II study (MEHGAN) evaluated 
drug efficacy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the 
head and neck (SCCHN) progressive on/after chemotherapy and among patients with 
NRG1-high tumors. Patients received duligotuzumab (1100 mg IV, q2w) or cetuximab 
(400 mg/m2 load, 250 mg/m2 IV, q1w) until progression or intolerable toxicity. Tumor 
samples were assayed for biomarkers [NRG1, ERBB3, and human papillomavirus (HPV) 
status].
results: Patients (N  =  121) were randomized (duligotuzumab:cetuximab; 59:62), 
median age 62 years; ECOG 0–2. Both arms (duligotuzumab vs. cetuximab, respec-
tively) showed comparable progression-free survival [4.2 vs. 4.0 months; HR: 1.23 (90% 
confidence interval (CI): 0.89–1.70)], overall survival [7.2 vs. 8.7 months; HR 1.15 (90% 
CI: 0.81–1.63)], and objective response rate (12 vs. 14.5%), with no difference between 
patients with NRG1-high tumors or ERBB3-low tumors. Responses in both arms were 
confined to HPV-negative patients. Grade ≥3 adverse events (AEs) (duligotuzumab vs. 
cetuximab, respectively) included infections (22 vs. 11.5%) and GI disorders (17 vs. 7%), 
contributing to higher rates of serious AEs (41 vs. 29.5%). Metabolic disorders were less 
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inTrODUCTiOn
Multiple members of the HER family receptor tyrosine kinases, 
including epidermal growth factor receptor (EGFR), HER1, and 
HER2, are established therapeutic targets in several epithelial 
malignancies (1). EGFR is a rational focus for squamous cell 
carcinoma of the head and neck (SCCHN) given the prevalence 
of its overexpression and crucial role in SCCHN pathogenesis 
(2, 3). Moreover, EGFR is a clinically validated therapeutic target 
in recurrent/metastatic SCCHN with approval of cetuximab as a 
single agent (4), concurrent with platinum-based chemotherapy 
(5), and in combination with radiotherapy in the curative SCCHN 
setting (6). Many SCCHN patients do not respond to cetuximab 
therapy, and for those who do, they commonly manifest acquired 
resistance following prolonged exposure to the drug. These 
findings have prompted the design of next-generation EGFR 
inhibitors and approaches that may serve to overcome resistance 
to cetuximab.
Factors thought to contribute to cetuximab resistance in 
SCCHN patients include upregulation of ligands for EGFR 
and human epidermal growth factor receptor 3 (HER3) 
(7, 8), heterodimerization of EGFR and HER2 with HER3 (9), 
overexpression of HER2 and HER3 (10), and overexpression 
and aberrant nuclear localization of EGFR (11). Interestingly, 
a subset of SCCHN cell lines are resistant to anti-EGFR tyros-
ine kinase inhibitor (TKI) treatment and do not overexpress 
HER2 but are sensitive to combined anti-EGFR/anti-HER2 
TKI inhibition (12). Many of these cell lines were found to 
have high expression of heregulin (HRG), the ligand binding to 
HER3, and activation of HER3 signaling. It was hypothesized 
that such cells may escape the effects of anti-EGFR therapy via 
HRG-dependent signaling of a HER2/HER3 dimer. An analysis 
of >700 tumor samples from patients with non-small cell lung 
cancer (NSCLC), SCCHN, colorectal, breast, or ovarian cancer 
found that median HRG mRNA expression is significantly 
higher in SCCHN tumors than in the other tumor types (13). 
HRG represents alpha and beta forms of neuregulin 1 (14) and 
is here forth referred to as NRG1.
Duligotuzumab (MEHD7945A) is a novel dual-action human 
IgG1 monoclonal antibody that simultaneously targets HER3 and 
EGFR (15). HER3 is encoded by the ERBB3 gene. Duligotuzumab 
demonstrated superior activity compared with mono-specific 
EGFR- or HER3-targeting antibodies in the non-clinical FaDu 
SCCHN model (16), as well as in human xenograft models derived 
from SCCHN and NSCLC tumors with acquired resistance to 
EGFR inhibitors (17). Preliminary evidence of clinical activity 
included two confirmed partial responses (PRs) in SCCHN 
patients (18) who had entered the duligotuzumab phase Ia study 
after progressing on prior therapy, one having relapsed after 
multiple prior treatment regimens including an EGFR inhibitor. 
Both patients’ tumors were found to have NRG1 expression near 
the top of the range observed in the analysis of tumor samples 
described above.
Taken together, these observations suggested that the addi-
tion of HER3 blockade to EGFR blockade with duligotuzumab 
may improve clinical outcomes in patients with recurrent or 
metastatic (R/M) SCCHN overall or specifically in those patients 
whose tumors express high levels of NRG1. This phase II study 
evaluated the efficacy of duligotuzumab vs. cetuximab in patients 
with R/M SCCHN progressive on/after chemotherapy and 
included post  hoc analyses by NRG1 expression levels, ERBB3 
expression levels, and human papillomavirus (HPV) status.
METHODS
Patients
Eligible patients were ≥18  years of age with histologically 
confirmed R/M SCCHN who had progressed after one or more 
lines of treatment, at least one platinum-based regimen for R/M 
disease, and not suitable for local therapy. Patients with ECOG 
performance status of 0, 1, or 2, disease measurable per RECIST 
v1.1, adequate hematologic, renal, or hepatic function, no prior 
HER targeted therapy with exception of EGFR inhibitor given 
in upfront setting and as long as discontinued ≥3 months prior 
to enrollment were included. Patients were excluded if they 
had nasopharyngeal cancer.
frequent with duligotuzumab (10 vs. 16%); any grade rash-related events were less with 
duligotuzumab (49 vs. 67%).
Conclusion: While several lines of preclinical evidence had supported the premise that 
the blockade of HER3 in addition to that of EGFR may improve outcomes for patients 
with R/M SCCHN overall or specifically in those patients whose tumors express high 
levels of NRG1, this study provided definitive clinical evidence refuting this hypothesis. 
Duligotuzumab did not improve patient outcomes in comparison to cetuximab despite 
frequent expression of NRG1. These data indicate that inhibition of EGFR alone is suffi-
cient to block EGFR–HER3 signaling, suggesting that HER2 plays a minimal role in this 
disease. Extensive biomarker analyses further show that HPV-negative SCCHN but not 
HPV-positive SCCHN are most likely to respond to EGFR blockage by cetuximab or 
duligotuzumab.
Keywords: nrG1, HEr3, EGFr, SCCHn, HPV, duligotuzumab, MEHD7945a, cetuximab
FiGUrE 1 | Study design.
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Study Design
This was a phase II, randomized, multicenter, open-label study 
with two arms (Figure 1) assessing duligotuzumab vs. cetuximab 
in R/M SCCHN patients. Institutional review boards at all par-
ticipating institutions approved the study protocol. All patients 
gave written informed consent. The study was conducted 
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according to good clinical practice (GCP), and the Declaration 
of Helsinki and its amendments, and was registered at http://
ClinicalTrials.gov, number NCT01577173 (19).
Patients received duligotuzumab, 1100  mg IV, administered 
every 2 weeks (Arm A), or cetuximab, 400 mg/m2 loading dose, 
250  mg/m2 IV, administered weekly (q1w) (Arm B). Patients 
were randomized to one of the two treatment arms in a 1:1 ratio 
using an interactive voice response system (IVRS). Stratification 
factors included ECOG 0/1 vs. 2 and time to platinum failure 
(≤2 vs. >2 months). Patients were treated with either study drug 
until disease progression or other unacceptable toxicity. Patients 
with disease progression on Arm B (cetuximab) could cross 
over to Arm A (duligotuzumab) upon central confirmation of 
progressive disease (PD) (RECIST v1.1), and as long as principal 
eligibility criteria were met.
The primary endpoint was progression-free survival (PFS) 
by investigator assessment in all randomized patients [intention 
to treat (ITT) population] and in the subset with highest NRG1 
expression in the tumor. NRG1 was assessed by qRT-PCR at 
Genentech. Secondary objectives included overall survival (OS), 
overall response rate (ORR), safety/tolerability, and characteriza-
tion of pharmacokinetics (PKs) and anti-therapeutic antibodies 
(ATA) from patients treated on Arm A. Exploratory objectives 
included assessing tumor samples from patients for the preva-
lence and potential prognostic significance of NRG1 and ERBB3, 
and HPV status and its potential association with antitumor 
activity.
Safety
Safety was assessed by incidence, nature, severity, and relatedness 
of adverse events (AEs) and graded for severity (NCI-CTCAE 
v4.0). All patients who received ≥1 dose of study treatment were 
included in the safety evaluation. The following events were 
categorized as of special interest: grade ≥3 events associated 
with infusion-related reactions (defined as AEs within 24  h of 
infusion and attributed to study drug), grade ≥3 rash, and grade 
≥3 diarrhea.
Pharmacokinetics
Serum samples were collected at screening, day 1 of cycles 1–8, 
and treatment completion. Duligotuzumab concentration was 
determined using a qualified enzyme-linked immunosorb-
ent assay with the minimum quantifiable concentration of 
150 ng/mL. PK parameters were derived from non-compartmen-
tal analysis (NCA) (WinNonlin version 5.2.1.). A population PK 
analysis of duligotuzumab from phase Ia study DAF4873g (data 
on file) demonstrated that body weight has only a minor impact 
on PK parameters [volume of distribution (Vd) and clearance 
(CL)], thus supporting that flat dosing would have little effect on 
duligotuzumab PK variability in comparison with weight-based 
dosing.
Serum anti-duligotuzumab antibody (ATA) samples were col-
lected prior to duligotuzumab infusion on day 1 of cycles 1–8, and 
at the study termination visit, and were analyzed using a validated 
bridging antibody immunoassay that could detect surrogate 
anti-duligotuzumab positive-control antibody (249  ng/mL) in 
the absence of duligotuzumab.
Biomarker analyses
Mandatory archival (or fresh as available) tumor tissues were 
evaluated to characterize the disease biology and to identify 
potential predictive biomarkers for improved outcomes with 
duligotuzumab compared to cetuximab, with particular atten-
tion to the HER3 ligand, NRG1. For NRG1 and receptor tyrosine 
kinase erbB-3 (ERBB3), RNA expressions were measured by 
both qRT-PCR and by dual-colored in situ hybridization (ISH). 
Additionally, HPV detection was performed by qRT-PCR.
Efficacy
Tumor assessments were performed at screening and during 
every 6 weeks of study treatment (e.g., prior to cycle 4 and every 
6  weeks thereafter), and at the treatment completion visit for 
patients who discontinue for reason other than PD. Response 
assessments were performed by the investigators according to 
RECIST v1.1. The primary endpoint was PFS, defined as the time 
from randomization to the first occurrence of progression or 
death, whichever occurred first. Secondary endpoints included 
OS (defined as the time from randomization to death) and objec-
tive response defined as complete response (CR) or PR confirmed 
≥4  weeks after initial documentation. Unless stated otherwise, 
analyses excluded data after crossover.
Sample Size
This trial was designed to obtain informative estimates of the 
PFS hazard ratios in the overall patient population, and the 
NRG1-high patient population to enable further decision mak-
ing, without adequate power to detect the minimum clinically 
meaningful difference between the treatment arms at a statisti-
cally significant type 1 error level (α = 0.05). Therefore, the utility 
of formal hypothesis testing was limited because statistically 
negative outcomes did not necessarily exclude clinically signifi-
cant treatment effects. Consequently, 90% CIs for the PFS hazard 
ratios were calculated. In order to observe 90 disease progression 
or death events in all patients and 35 disease progression or death 
events in the NRG1-high patients, the study was planned to enroll 
110 patients, assuming the prevalence of NRG1-high patients was 
40%. For a lower prevalence, additional patients could be enrolled 
to meet the required number of disease progression or death 
events in the HRG-high patient population.
Statistical analysis
Safety analyses included all patients who received any amount 
of study treatment. Efficacy analyses were conducted on all ran-
domized patients and all randomized NRG1-high patients. For 
each time-to-event endpoint, Kaplan–Meier analysis was used to 
estimate the medians in each treatment arm, and Cox regression 
was used to estimate the hazard ratio.
rESUlTS
Patient Population
From July 13, 2012 to July 09, 2013, 121 patients were randomized 
(59 Arm A, 62 Arm B), of whom 120 were evaluable for safety, 
108 for biomarker analysis, and 22 during the crossover phase. 








Median (range) 62.0 (29–80) 62.0 (28–84) 62.0 (28–84)
Sex
Male 55 (93%) 46 (75%) 101 (84%)
race
White 47 (80%) 45 (74%) 92 (77%)
Tobacco use history
Never 12 (20%) 8 (13%) 20 (17%)
ECOG performance statusa
0/1 50 (85%) 52 (85%) 102 (85%)
Time to progressive disease since last platinum-based chemoa
≤2 months 31 (53%) 34 (55%) 65 (54%)
Site of primary tumor
Oral cavity 15 (25%) 20 (32%) 35 (29%)
Oropharynx 16 (27%) 20 (32%) 36 (30%)
Larynx 11 (19%) 8 (13%) 19 (16%)
Hypopharynx 6 (10%) 6 (10%) 12 (10%)
Head and neck 7 (12%) 5 (8%) 12 (10%)
Unknown primary site 4 (7%) 3 (5%) 7 (6%)
HPV (qrT-PCr assay)
Positive 10 (17%) 15 (24%) 25 (21%)
Prior therapies, n (%)
Radiation therapy 52 (88%) 52 (84%) 104 (86%)
number of prior systemic regimen
Median (range) 2 (1–5) 1 (1–5) 1 (1–5)
Extent of disease at baseline
Locoregional recurrence only 7 (12%) 14 (23%) 21 (17%)
aStratification factor.
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The cutoff date for analysis was March 02, 2015, resulting in a 
minimum follow-up of 19.8 months.
Key baseline characteristics included the stratification 
factors, ECOG, and time to PD, since most recent platinum 
treatment were well-balanced overall (Table 1) with the excep-
tion of fewer HPV-positive patients and fewer patients with 
locoregional recurrence only who enrolled on the experimental 
duligotuzumab arm, as compared to the cetuximab arm. Upon 
review of staging and prior medical history, it was identified that 
25/121 patients were enrolled in the first line (1L) rather than 
the protocol specified 2L + R/M setting. Those patients had not 
received prior platinum-based therapy for de novo metastatic 
(Stage IVc) or for recurrence of locally advanced disease, but 
rather in the adjuvant or definitive setting. Subset analyses 
excluding those 25 patients showed no significant impact on 
the efficacy results.
Study Treatment
The median number of doses given of duligotuzumab was 7 
(range 1–24) and of cetuximab 12 (range 1–59). The median 
treatment duration for duligotuzumab and cetuximab was 12.4 
and 12.0 weeks, respectively. The median relative cumulative dose 
intensity for duligotuzumab and cetuximab was 87.5 and 89.8%, 
respectively. Treatment modification or interruption was similar 
for duligotuzumab and cetuximab, with 42 (71%) patients miss-
ing at least one dose in the duligotuzumab arm and 49 (80%) in 
the cetuximab arm. There were 2 (3%) dose modifications in the 
duligotuzumab arm and 11 (18%) in the cetuximab arm.
The majority of study treatment discontinuations were due to 
radiographic disease progression or symptomatic deterioration 
[73% duligotuzumab (radiographic PD: 64%); 80% cetuximab 
(radiographic PD: 69%)]. Twenty-two patients crossed over 
to duligotuzumab after central confirmation of progression on 
cetuximab. Median treatment duration and cumulative dose 
intensity were 7.6 months and 88.9% for duligotuzumab, respec-
tively. One patient continues duligotuzumab in the crossover arm.
Safety
The nature and incidence of AEs in the 120 patients evaluable 
for safety regardless of attribution are summarized (Table  2). 
The most common AEs were rash (and related terms), infections 
(MedDRA System Order Class), diarrhea, fatigue, and nausea. 
The safety profile of duligotuzumab was largely similar to that of 
cetuximab, however, relative to cetuximab, duligotuzumab was 
associated with less rash (49 vs. 65%), but more diarrhea (42 vs. 
25%), mucosal inflammation (22 vs. 8%), and infection (59 vs. 
49%). Grade ≥3 AEs were more frequent in the duligotuzumab 
arm (61%) vs. the cetuximab arm (51%). Seven deaths (five in the 
duligotuzumab arm; two in the cetuximab arm), none of which 
were assessed as related to study treatment, were attributed to 
underlying disease, disease progression, or an unknown cause.
Infusion-related reactions of headache and fever (events 
observed within 24  h of treatment and reported as related to 
study treatment; grade 1–2) had a higher incidence in the duli-
gotuzumab arm (13 vs. 3% for headache and 10 vs. 5% for fever). 
No allergic type infusion-related reactions were observed in the 
duligotuzumab arm; anaphylactic reactions to cetuximab were 
reported in 3% of patients. Discontinuations due to AEs were 
higher in the cetuximab arm (7% duligotuzumab and 13.5% 
cetuximab).
Pharmacokinetics
Target exposures of duligotuzumab were achieved in 100% of 
patients. The mean steady state (cycle 4) duligotuzumab PK 
parameter values (SD) for predose and Cmax were 82.4 (40.4) 
and 366 (106) μg/mL, respectively. There was a weak trend 
observed in PK vs. body weight. No PK differences were detected 
in patient subpopulations (NRG1 high/low or HPV+/−). ATAs 
were detected in 2/61 patients (3.3%) and had no impact on PK 
or safety.
Clinical activity
In the ITT population, duligotuzumab and cetuximab showed 
comparable PFS [median 4.2 vs. 4.0  months, respectively, 
unstratified HR 1.23 (90% CI 0.89–1.70)] and OS [median 
7.2 vs. 8.7  months, respectively, unstratified HR 1.15 (90% CI 
0.81–1.63)] (Figure 2). PFS and OS subgroup analysis by patient 
and disease characteristics and stratification factors (ECOG and 
time to PD since most recent platinum treatment) did not show 
benefit for duligotuzumab over cetuximab. Objective response 
and treatment duration were comparable: ORR 12% (7 patients) 
duligotuzumab vs. 14.5% (9 patients) cetuximab, duration of 
objective response was median 5.4 months (duligotuzumab) vs. 
TaBlE 2 | adverse events reported in ≥15% of patients in either arm regardless of attribution.
Duligotuzumab (n = 59) Cetuximab (n = 61)
MedDra preferred term any grade Grade ≥3 any grade Grade ≥3
All 58 (98%) 36 (61%) 59 (97%) 31 (51%)
Rash and related MedDRA Termsa 29 (49%) – 40 (66%) 4 (7%)
Infections and infestations MedDRA SOCb 35 (59%) 13 (22%) 30 (49%) 7 (12%)
Diarrhea 25 (42%) 2 (3%) 15 (25%) –
Fatigue 19 (32%) 2 (3%) 18 (29.5%) 1 (2%)
Nausea 13 (22%) – 18 (29.5%) –
Hypomagnesemia 12 (20%) 1 (2%) 16 (26%) 3 (5%)
Vomiting 12 (20%) – 11 (18%) –
Pyrexia 15 (25%) – 6 (10%) –
Headache 15 (25%) – 6 (10%) –
Skin fissures 11 (19%) – 8 (13%) 1 (2%)
Decreased appetite 10 (17%) 1 (2%) 10 (16%) 1 (2%)
Mucosal inflammation 13 (22%) – 5 (8%) –
Weight decreased 6 (10%) – 10 (16%) 1 (2%)
Constipation 9 (15%) – 7 (11.5%) –
Dry skin 8 (14%) – 10 (16%) –
Dyspnea 7 (12%) 1 (2%) 11 (18%) 4 (7%)
Asthenia 6 (10%) 1 (2%) 10 (16%) 1 (2%)
AEs presented are prior to crossover; AEs in crossover arm not reported here but similar.
aRash and related MedDRA terms = dermatitis acneiform, rash, rash maculo-papular, rash macular, rash erythematous, rash pruritic, rash generalized, rash papular, rash pustular, 
genital rash, and mucocutaneous rash.
bMedDRA System Order Class Infections and Infestations terms: paronychia (22% in duligotuzumab arm vs. 10% in cetuximab arm; No Grade 3 AEs), conjunctivitis, pneumonia, 
respiratory tract infection, bronchitis, lower respiratory tract infection, oral candidiasis, Candida infection, folliculitis, oral fungal infection, upper respiratory tract infection, cellulitis, 
sepsis, urinary tract infection, device-related infection, infection, nasopharyngitis, lung infection, nail infection, pharyngitis, oral herpes, abscess, abscess neck, bacteremia, 
Clostridium difficile infection, ear infection, fungal infection, groin abscess, infected bites, influenza, meningitis, mucosal infection, onychomycosis, osteomyelitis, rash pustular, rhinitis, 
skin bacterial infection, skin infection, staphylococcal infection, viral upper respiratory tract infection, abscess limb, acute sinusitis, bacteriuria, furuncle, herpes zoster, infected fistula, 
oral infection, pneumonia necrotizing, sinusitis, stoma site infection, and tracheostomy infection.
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4.3 months (cetuximab). There was limited evidence of activity in 
crossover patients (n = 22) (Figure 3).
Best responses in the duligotuzumab arm included 1 (2%) CR, 
8 (14%) PRs, and 36 (61%) individuals with stable disease. The 
cetuximab arm included 2 (3%) CRs, 11 (18%) PRs, and 25 (40%) 
individuals with stable disease. Of 22 patients who crossed over to 
duligotuzumab after cetuximab failure, 10 showed stable disease 
(45%), exceeding prior PFS on cetuximab in 5 patients, and with 
one patient remaining active on study.
Biomarker Subset analyses
Biomarker subtype analysis was performed for NRG1 and ERBB3 
in 108 tumor samples (89%; 51/59 in the duligotuzumab arm and 
57/62 in the cetuximab arm), both potential indicators of HER3 
activity. Baseline expression using median and quartile cutoffs, 
respectively, was assessed relative to best change in sum of longest 
diameters of lesions from baseline and PFS. While there appeared 
to be a trend toward elevated NRG1 levels and an increase in 
tumor shrinkage (Figure 4A), neither elevated NRG1 nor reduced 
ERBB3 expression predicted for response to duligotuzumab or 
against response to cetuximab (Figure 4B). Moreover, the trend 
toward elevated NRG1 expression and increased tumor shrink-
age was observed in both study arms. Similar observations were 
made for OS. Of note, NRG1 expression levels were comparable 
to those in the phase Ia study (including responders) (18). To 
further address the hypothesized and preclinically supported 
role for NRG1 autocrine expression in SCCHN, dual-colored 
ISH (NRG1 and ERBB3) was performed and the biomarker 
analysis was repeated. Similar to expression analysis, co-localized 
expression of NRG1 and ERBB3 did not predict for response to 
duligotuzumab (Figure 4C).
In addition to molecular biomarkers, HPV status based on 
qRT-PCR methodology was performed. Of 110 evaluable tumor 
samples from both treatment arms, 25 were HPV-positive and 
85 HPV-negative. HPV-negative samples tended to have higher 
NRG1 ligand expression. Of the 25 patients with HPV-positive 
tumors, the site of primary tumor was oropharynx (14), oral cav-
ity (4), larynx (1), and other or unknown locations (6). Among 
HPV-positive patients treated with either duligotuzumab or 
cetuximab, there were no responses (Figure 5).
DiSCUSSiOn
The results of this phase II study show that dual inhibition of 
HER3 and EGFR by single-agent duligotuzumab demonstrated 
activity comparable, but not superior, to single-agent cetuximab 
in second or more line R/M SCCHN. High NRG1 gene expres-
sion in tumor (primary biomarker hypothesis) was not associ-
ated with duligotuzumab efficacy as response rates, and PFS 
was similar between groups. Similarly, no association was found 
with ERBB3 gene expression. Target study drug exposures were 
achieved for duligotuzumab. The phase II fixed dose of 1100 mg 
q2w duligotuzumab, which provides equivalent exposure to the 
phase Ia expansion dose of 14 mg/kg q2w, was selected based on 
achieving PK targets in >80% of patients. PK targets included an 
AUC based on xenograft models (equivalent to 300 day × μg/ml) 
FiGUrE 2 | Duligotuzumab vs. cetuximab in intention to treat (iTT) population showing comparable antitumor activity. (a) Progression-free survival.  
(B) Overall survival.
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FiGUrE 3 | Orr and treatment duration for primary treatment arms and crossover patients. (a) Duligotuzumab arm. (B) Cetuximab arm.
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FiGUrE 4 | Efficacy relative to key biomarkers: (a) best change in target lesion sum of longest dimension (SlD) and corresponding NRG1, ERBB3, 
and HPV status; (B) PFS by NRG1 and ERBB3 expression levels by quartiles; and (C) NRG1 measured by qrT-PCr or by iSH does not predict 
response to duligotuzumab.
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FiGUrE 5 | HEr family ligand expression by HPV status. Ligand 
expression was higher in HPV-negative (−) subjects, with no responses in 
HPV-positive (+).
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and a C-trough of 5.3 μg/ml, which is predicted to correspond to 
90% target saturation and 95% receptor binding. There was no 
clear relationship between exposure to duligotuzumab and safety 
or efficacy.
The safety profile of duligotuzumab was largely similar to 
cetuximab, with few exceptions. While duligotuzumab was 
associated with fewer rash events (49 vs. 65%) compared to 
cetuximab, GI disorders were more frequent with duligotuzumab 
vs. cetuximab (diarrhea 42 vs. 25%; mucosal inflammation 22 
vs. 8%). These observations are consistent with other regimens 
targeting multiple HER receptors, and likely indicative of HER3-
mediated toxicity [e.g., pan-HER TKI afatinib vs. cetuximab 
in R/M SCCHN (20); addition of pertuzumab (inhibitor of the 
dimerization of HER2/HER3) to trastuzumab and chemotherapy 
in 1L HER2 + breast cancer (21)]. MedDRA System Order Class 
“Infections and Infestations” were more frequent in the duligotu-
zumab arm (all grades: 59 vs. 49%; grades ≥3: 22 vs. 12%) with no 
particular pattern of infection identified in either treatment arm. 
The higher frequency in duligotuzumab-treated patients may be 
related to this groups’ higher rate of mucosal inflammation.
Despite strong preclinical data coupled with activity in phase 
I suggesting a potential role of HER3 signaling in SCCHN (16, 
18), the dual inhibition of EGFR and HER3 was not associated 
with improved efficacy in this study, neither in all randomized 
nor biomarker positive patients. The outcome was similar in 
study of the pan-HER TKI, afatinib vs. cetuximab in all-comer 
≥1L SCCHN (20), with median PFS 13.0 vs. 15.0  weeks (HR 
0.93, 95% CI 0.62–1.38, p =  0.71). Median PFS for patients 
who crossed over to afatinib was 9.3 and 5.7  weeks for those 
crossing to cetuximab (HR 0.64, 95% CI 0.38–1.05, p = 0.08). 
Taken together, these data suggest that the inhibition of HER3 
in addition to EGFR does not significantly improve response 
in recurrent/metastatic SCCHN. Alternatively, these data may 
indicate that inhibition of EGFR alone may be sufficient to 
block EGFR–HER3 signaling, suggesting that HER2 plays a 
minimal role in this disease. A better understanding of receptor 
dimerization following exposure to different agents may provide 
critical insights to this mechanism. It is also possible that HER3 
signaling has a moderate role in SCCHN and inhibition of HER3 
by duligotuzumab compensated for its slightly lower affinity 
for EGFR (Kd of 0.4  nM vs. 0.39  nM for cetuximab) (16, 22). 
Finally, there is no evidence for differential ADCC activity as 
duligotuzumab demonstrated mediated ADCC activity in cell 
lines with high EGFR expression that was similar to what has 
been described with cetuximab (16).
The potential for enhanced chemosensitization and radiosen-
sitization with dual HER3/EGFR inhibition remains an unan-
swered question. Preclinical studies showed enhanced radiation 
response with dual HER3/EGFR inhibition in SCCHN and lung 
cancer model systems (23). Chemotherapy-induced upregulation 
of NRG1 and activation of HER3 have been reported in  vitro 
(24). A phase Ib study combining duligotuzumab with either 
cisplatin/5FU or carboplatin/paclitaxel in 1L R/M, SCCHN 
showed encouraging activity with ORR of 67% though without 
clear relationship with evaluated biomarkers and hence no means 
for patient selection (25, 26). While the phase Ib study showed 
high antitumor efficacy and a higher frequency and severity of 
select AEs in comparison to historical phase III data on combina-
tion of chemotherapy and EGFR inhibitors, it is not clear if such 
was owed to chemo sensitization or rather was reflective of the 
small sample size.
The role of EGFR inhibition in HPV-associated oropharyngeal 
cancer vs. HPV-negative head and neck cancer remains controver-
sial and may differ depending on whether given as monotherapy 
or combined with chemotherapy or radiotherapy. Our findings 
of no objective responses in the HPV-positive group with either 
agent are consistent with those recently reported with afatanib 
(27), with no objective responses in the p16-positive population 
and a 13.5% response rate in the p16-negative population, and 
raise further doubts about the role of anti-EGFR monotherapy 
for R/M HPV-associated oropharyngeal cancer.
COnClUSiOn
Dual inhibition of EGFR and HER3 by duligotuzumab was 
not associated with improved efficacy compared to cetuximab, 
neither in all randomized nor biomarker positive patients. Our 
data suggest that HPV-negative SCCHN but not HPV-positive 
SCCHN may respond to cetuximab or duligotuzumab, though 
the addition of HER3 inhibition does not significantly improve 
response but may increase the frequency of select lower grade 
GI toxicities.
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